WASHINGTON, D.C. – Today, U.S. Senator Jacky Rosen (D-NV) released the following statement applauding actions taken by the Biden Administration to support the United States’ efforts in combating the COVID-19 pandemic:
“I am glad to see the Biden Administration’s swift and focused efforts to defeat COVID-19,” said Senator Rosen. “One year ago today, the first case of coronavirus was confirmed in the United States by the U.S. Centers for Disease Control and Prevention. In the 12 months since, Nevadans and Americans across our nation have experienced great loss and tremendous hardship. President Biden’s actions will ramp up our efforts to beat this virus by strengthening the pandemic supply chain, increasing preventive measures against COVID-19, accelerating the production of therapeutics, and expanding our capacity to treat patients. As we enter this new phase, I will continue working in the Senate and with this Administration to protect the lives and livelihoods of Nevadans.”
BACKGROUND: Last week, Senator Rosen joined colleagues in a letter to the then-incoming Biden Administration requesting a waiving of the state cost-share requirement for FEMA assistance related to the novel coronavirus (COVID-19) pandemic.
Last week, Senator Rosen also joined colleagues in a letter to then-Health and Human Services (HHS) Secretary Alex Azar demanding the then-Trump Administration take immediate action to fix the significant failures of the COVID-19 vaccine distribution as coronavirus cases continue to climb.
In November, Senator Rosen joined colleagues in a letter to then-Secretary Azar and FEMA Director Peter Gaynor, requesting the agencies provide additional health care professionals to states experiencing a surge in COVID-19 cases and a shortage of medical staff available to treat infected patients.
In May of last year, Senator Rosen and Senator Marco Rubio (R-FL) introduced the Ensuring Understanding of COVID-19 to Protect Public Health Act, bipartisan legislation that would direct the National Institutes of Health (NIH) to conduct a longitudinal study on mild, moderate, and severe cases of COVID-19 on a diverse patient population to ensure the U.S. gains a full understanding of both the short and long-term health impacts of the novel coronavirus.